Approved for use through 07/31/2060. OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(0) M 12 (2)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of Sheet

Complete if Known				
Application Number	10/529,612			
Filing Date	November 12, 2003 (PCT) March 30, 2005 (371)			
First Named Inventor	KENNETH ANDREW HUGHES ET AL.			
Group Art Unit	1616			
Examiner Name	UNKNOWN			
Attorney Docket Number	BA9313USPCT			

	U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No.1		ocument Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US -	5,998,424	12-07-1999	Robert A. Galemmo, Jr. et al.	
	2	US -	6,403,620	06-11-2002	Robert A. Galemmo, Jr. et al.	
	3	US -	6,602,895	08-05-2003	Robert A. Galemmo, Jr. et al.	
	4	US -	6,548,512	04-15-2003	Donald Joseph Phillip Pinto et al.	
	5	US -	6,020,357	02-01-2000	Donald Joseph Phillip Pinto et al.	
		US -				
		US-				
		US -				
		US-				
		US -				
		US -				
		US -				
	Ī	US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		CountryCode ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			T _β		
	6	WO98/28269	07-02-1998	DuPont Merck Pharmaceutical Company				
	7	WO98/57937	12-23-1998	DuPont Merck Pharmaceutical Company				
	8	EP 0 991 625 B1	06-01-2005	Bristol-Myers Squibb Pharma Company				
	9	EP 0 946 508 A1	10-06-1999	Bristol-Myers Squibb Pharma Company				

Examiner Signature	/Sabiha Qazi/	Date Considered	08/04/2008

EXAMINENCE INITIAL IT reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.agov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.